Department of Global Public Health, Karolinska Institutet, Solnavägen 1 E, 11365 Stockholm, Sweden.
Surgical Clinic, Department of Clinical and Experimental Sciences, University of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy.
Clin Res Hepatol Gastroenterol. 2021 Jan;45(1):101433. doi: 10.1016/j.clinre.2020.04.004. Epub 2020 May 12.
Improvement of survival rates for hepatocellular carcinoma during the last two decades and related factors are still debated. This study aimed to evaluate the risk of death and the role of prognostic factors in patients with hepatocellular carcinoma diagnosed in 1995-2001 and 2004-2006.
We performed univariate and multivariable survival analyses of subjects with a first hepatocellular carcinoma diagnosis in 1995-2001 and in 2004-2006, all residing in Brescia province, Italy. Mediation analysis of treatment role in survival was conducted.
During follow-up (median 21.1 months) 913 subjects died (95.5%). The 1-, 3- and 5-year survival rates were higher for cases diagnosed in 2004-2006 (64.4%, 35.9% and 24.3%) than in 1995-2001 (60.8%, 34.5% and 20.7%). T stage, metastasis, cirrhosis, Child-Pugh class, portal vein invasion, serum creatinine level, treatment approach and diabetes were survival predictors in both periods. Patients with diagnosis in 2004-2006 had 36% lower risk of death than those with diagnosis in 1995-2001 using adjusted Cox proportional hazard model. The association between diagnosis period and risk of death was mediated by changes in treatment approach.
We observed a decreased risk of death for first hepatocellular carcinoma diagnosis from 2004-2006 to 1995-2001, which was partially attributable to improvements in treatment approach.
在过去的二十年中,肝细胞癌的生存率得到了提高,相关因素仍存在争议。本研究旨在评估 1995-2001 年和 2004-2006 年诊断的肝细胞癌患者的死亡风险和预后因素的作用。
我们对 1995-2001 年和 2004-2006 年首次诊断为肝细胞癌的患者进行了单因素和多因素生存分析,所有患者均居住在意大利布雷西亚省。对治疗在生存中的作用进行了中介分析。
在随访期间(中位 21.1 个月),913 例患者死亡(95.5%)。2004-2006 年诊断的病例的 1、3 和 5 年生存率分别为 64.4%、35.9%和 24.3%,高于 1995-2001 年的 60.8%、34.5%和 20.7%。T 分期、转移、肝硬化、Child-Pugh 分级、门静脉侵犯、血清肌酐水平、治疗方法和糖尿病是两个时期的生存预测因素。调整后的 Cox 比例风险模型显示,2004-2006 年诊断的患者死亡风险比 1995-2001 年诊断的患者低 36%。诊断期与死亡风险之间的关联部分由治疗方法的变化介导。
我们观察到,2004-2006 年首次诊断为肝细胞癌的患者死亡风险较 1995-2001 年有所降低,这部分归因于治疗方法的改进。